Track topics on Twitter Track topics that are important to you
ZUG, Switzerland, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important medical needs in otolaryngology, today announced that it will release its financial results for the second quarter 2015 on Wednesday, August 19, 2015. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the second quarter 2015 and provide a general business update.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Auris Medical Q2 2015 Earnings Release Date 2015-08-12 http://hugin.info/160190/R/1945084/705082.pdf
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Hearing, auditory perception, or audition is the ability to perceive sound by detecting vibrations, changes in the pressure of the surrounding medium through time, through an organ such as the ear. Sound may be heard through solid, liquid, or gaseous mat...